See the DrugPatentWatch profile for Edaravone
Edaravone is a free radical scavenger used to treat amyotrophic lateral sclerosis (ALS). The active pharmaceutical ingredient (API) is synthesized through chemical processes.
How is Edaravone API Made?
The synthesis of edaravone involves several chemical steps. One common method starts with the reaction of phenylhydrazine with ethyl acetoacetate to form 1-phenyl-3-methyl-5-pyrazolone. This intermediate is then reacted with formaldehyde to produce 2-phenyl-3-methyl-5-oxo-2,5-dihydro-1H-pyrazole-1-carboxaldehyde, which upon further treatment yields edaravone. Different synthetic routes may exist, and manufacturers optimize these processes for yield, purity, and cost-effectiveness.
Who Manufactures Edaravone API?
Several pharmaceutical companies and chemical manufacturers produce edaravone API. The specific manufacturers can vary by region and market. For example, companies involved in producing generic versions of edaravone-based drugs often source their API from specialized API manufacturers. Information on specific API suppliers can be found through industry databases and trade resources.
When Does Edaravone Patent Protection End?
Patent protection for edaravone and its associated formulations varies depending on the specific patents and the country. DrugPatentWatch.com tracks these patents and their expiry dates. For instance, patents related to the initial discovery or novel formulations of edaravone may have different expiry timelines than those covering manufacturing processes or new uses. Understanding these patent landscapes is crucial for generic manufacturers and for assessing market exclusivity. You can explore patent details for edaravone on DrugPatentWatch.com [1].
What Are the Uses of Edaravone?
Edaravone, marketed under brand names like Radicava and Radicut, is approved for the treatment of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease. It works by scavenging free radicals, which are believed to play a role in the neuronal damage seen in ALS. Clinical studies have shown that edaravone can slow the decline in physical function in some ALS patients [2].
What Are the Risks and Side Effects of Edaravone?
Common side effects of edaravone include bruising, gait disturbance, headache, and dermatitis. More serious but less common side effects can include hypersensitivity reactions, such as anaphylaxis, and neurogenic bladder. Patients receiving edaravone require careful monitoring for these adverse events [3].
Can Biosimilars of Edaravone Be Developed?
Edaravone is a small molecule drug, not a biologic. Therefore, the concept of biosimilars, which applies to biologic drugs, does not directly apply. However, generic versions of edaravone can be developed and approved once the relevant patents expire and other regulatory requirements are met. The pathway for generic drug approval focuses on demonstrating bioequivalence to the reference listed drug.
How Does Edaravone Compare to Other ALS Treatments?
Edaravone is one of several treatments available for ALS, though it is one of the few that has demonstrated a benefit in slowing functional decline. Other approved treatments include riluzole, which also aims to slow disease progression, and newer medications that target specific pathways or symptoms. The choice of treatment depends on the individual patient's disease stage, symptoms, and response to therapy [2].
Sources:
[1] DrugPatentWatch.com
[2] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-recalls-company-communications-and-safety-information
[3] https://www.radicava.com/